Shire plc: Change to Director's Details
Posted on: Thursday, 5 February 2009, 15:05 CST
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: http://www.shire.com.
For further information please contact: Investor Relations Clea Rosenfeld (Rest of the World) +44-1256-894-160 Eric Rojas (North America) +1-617-551-9715 Media Matthew Cabrey (Specialty Pharma) +1-484-595-8248 Jessica Cotrone (HGT) +1-617-613-4640SOURCE Shire plc
Source: PR Newswire
Related Articles
- Shire's Project Playground Gives Boost to Philadelphia
- Vitesse Elects Willow B. Shire to Board of Directors
- Shire Pharmaceuticals Buys New River
- Shire Says Wants More Study on ADHD Side Effects
- Shire Presents Positive Results of Hunter Syndrome Pivotal Clinical Trial at The American Society of Human Genetics Annual Meeting
- Shire and Noven Resubmitted NDA for MTS, a Candidate Treatment for Pediatric ADHD Patients
- FDA Expands Indication for ADDERALL XR(R) (CII) Confirming Safety and Efficacy in Adolescents
- Statement on Release of Positive TKT Hunter Syndrome Data
- Shire and Noven Announce Positive Clinical Data for Transdermal ADHD Treatment
- Long-Term Study Demonstrated ADDERALL XR(R) (CII) is an Effective Option to Treat Adolescents With ADHD
 |
 |
User Comments (0)
RSS Feeds